Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to assess whether an adaptation of cyclosporine (CsA) dose according to a longitudinal calcineurin (CN) activity monitoring would prevent the onset of graft-versus-host disease (GVHD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: Agence de La Biomédecine
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Patients were between the age of 12 and 60 years

• Patients planned to receive an allogeneic HSCT following a myeloablative conditioning regimen

Exclusion Criteria:

• Transplant from a syngeneic donor

• Evidence of refractory disease

• Nonmyeloablative conditioning

• Any participation to a study with a new investigational drug within the previous 3 months